Fosamprenavir

Contraindicated

Fosamprenavir Simvastatin Flolipid Explained An increased risk of myopathy or rhabdomyolysis Details Fosamprenavir Alfuzosin UroXatral Increased alfuzosin plasma concentrations Details Fosamprenavir Dihydroergotamine Injection DHE-45® Injection Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, peripheral vasospasm, and peripheral isc... Details Fosamprenavir Dihydroergotamine Nasal Spray Migranal Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, peripheral vasospasm, and peripheral isc... Details Fosamprenavir Lovastatin Altocor® An increased risk of myopathy or rhabdomyolysis Details Fosamprenavir Maraviroc Selzentry Increased maraviroc concentrations Details Fosamprenavir Midazolam Nasal Spray Nayzilam An increased risk of midazolam toxicity (excessive sedation, confusion, respiratory depression) Details Fosamprenavir Midazolam Injection Nayzilam An increased risk of midazolam toxicity (excessive sedation, confusion, respiratory depression) Details

Major

Fosamprenavir Acetaminophen And Codeine Capital® & Codeine Explained Increased codeine and morphine exposure Details Fosamprenavir Abametapir Explained Increased exposure of CYP3A4 substrate Details Fosamprenavir Buprenorphine Belbuca Explained Increased buprenorphine exposure and an increased risk of buprenorphine-related adverse events Details Fosamprenavir Colchicine Colcrys Explained Increased colchicine exposure and an increased risk of fatal toxicity Details Fosamprenavir Atogepant Qulipta Reduced atogepant exposure Details Fosamprenavir Avapritinib Ayvakit Increased avapritinib exposure and an increased risk of the incidence and severity of adverse reactions Details Fosamprenavir Atorvastatin Atorvaliq Increased atorvastatin exposure and an increased risk of myopathy or rhabdomyolysis Details Fosamprenavir Cariprazine Vraylar Explained Increased cariprazine and its major active metabolite (didesmethylcariprazine (DDCAR)) exposure Details Fosamprenavir Amlodipine Amvaz® Increased amLODIPine exposure, an increased risk of hypotension and edema and reduced amLODIPine exposure Details Fosamprenavir Bedaquiline Sirturo Increased bedaquiline exposure Details Fosamprenavir Bosutinib Bosulif Increased bosutinib exposure Details Fosamprenavir Brexpiprazole Rexulti Increased brexpiprazole exposure Details Fosamprenavir Budesonide Entocort Increased budesonide exposure Details Fosamprenavir Budesonide Nasal Spray Rhinocort Increased budesonide exposure Details Fosamprenavir Budesonide Oral Inhalation Pulmicort Increased budesonide exposure Details Fosamprenavir Cabotegravir Apretude Loss of virologic response and possible development of viral resistance Details Fosamprenavir Cyclophosphamide Cytoxan® Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Fosamprenavir Cyclophosphamide Injection Cytoxan® Injection Increased risk of chemotherapy-induced mucositis, neutropenia, and infection Details Fosamprenavir Cyclosporine Injection Atopica Increased cycloSPORINE exposure Details Fosamprenavir Cyclosporine Ophthalmic Cequa Increased cycloSPORINE exposure Details Fosamprenavir Dexamethasone Injection Decadron Decreased plasma concentrations of amprenavir, the active metabolite of fosamprenavir Details Fosamprenavir Dexamethasone Ophthalmic Dexacidin® (as a combination product containing Dexamethasone, Neomycin, Polymyxin B) Decreased plasma concentrations of amprenavir, the active metabolite of fosamprenavir Details Fosamprenavir Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Reduced dolutegravir exposure and reduced efficacy of dolutegravir Details Fosamprenavir Doxorubicin Adriamycin Increased doxorubicin exposure and an increased risk of doxorubicin-related adverse reactions Details Fosamprenavir Encorafenib Braftovi Increased encorafenib exposure and an increased risk of encorafenib-related adverse events Details Fosamprenavir Entrectinib Rozlytrek Increased entrectinib exposure and an increased frequency or severity of adverse reactions Details Fosamprenavir Estradiol Delestrogen Reduced amprenavir exposure, altered hormonal levels, loss of contraceptive efficacy, and an increased risk of liver enzyme elevat... Details Fosamprenavir Estradiol Topical Divigel Reduced amprenavir exposure, altered hormonal levels, loss of contraceptive efficacy, and an increased risk of liver enzyme elevat... Details Fosamprenavir Estradiol Transdermal Patch Alora® Reduced amprenavir exposure, altered hormonal levels, loss of contraceptive efficacy, and an increased risk of liver enzyme elevat... Details Fosamprenavir Famotidine Calmicid Decreased fosamprenavir absorption and reduction of amprenavir efficacy (active fosamprenavir metabolite) Details Fosamprenavir Famotidine Injection Calmicid Decreased fosamprenavir absorption and reduction of amprenavir efficacy (active fosamprenavir metabolite) Details Fosamprenavir Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details